👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

BRIEF-AstraZeneca enters licensing agreements with Leo Pharma in skin diseases

Published 2016-07-01, 02:18 a/m
© Reuters.  BRIEF-AstraZeneca enters licensing agreements with Leo Pharma in skin diseases
AZN
-

July 1 (Reuters) - AstraZeneca AZN.L
* Enters licensing agreements with Leo Pharma in skin
diseases
* Agreement for development and commercialisation of
tralokinumab for atopic dermatitis supports sharper focus on
main therapy areas
* Also licenses European rights to Leo Pharma for
Brodalumab, a potential new medicine for psoriasis
* Leo Pharma will make upfront payment to Astrazeneca of
$115 million for rights to tralokinumab in atopic dermatitis and
any future indications
* Leo Pharma to also pay up to $1 billion in milestones and
up to mid-teen tiered percentage royalties on product sales
* Astrazeneca will retain all rights to tralokinumab in
respiratory disease and any other indications outside of
dermatology.
* Leo Pharma will gain european rights to brodalumab under
similar terms to those agreed with Valeant

Source text for Eikon: ID:
Further company coverage: AZN.L

(London Newsroom)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.